Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.
SGLT2
diabetes
diabetic kidney disease
glycosuria
ketosis
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
07
2021
accepted:
14
10
2021
entrez:
18
11
2021
pubmed:
19
11
2021
medline:
19
2
2022
Statut:
epublish
Résumé
As the prevalence of diabetic kidney disease (DKD) continues to rise, so does the need for a novel therapeutic modality that can control and slow its progression to end-stage renal disease. The advent of sodium-glucose cotransporter-2 (SGLT2) inhibitors has provided a major advancement for the treatment of DKD. However, there still remains insufficient understanding of the mechanism of action and effectiveness of this drug, and as a result, its use has been very limited. Burgeoning evidence suggests that the SGLT2 inhibitors possess renal protective activities that are able to lower glycemic levels, improve blood pressure/hemodynamics, cause bodyweight loss, mitigate oxidative stress, exert anti-inflammatory and anti-fibrotic effects, reduce urinary albumin excretion, lower uric acid levels, diminish the activity of intrarenal renin-angiotensin-aldosterone system, and reduce natriuretic peptide levels. SGLT2 inhibitors have been shown to be safe and beneficial for use in patients with a GFR ≥30mL/min/1.73m
Identifiants
pubmed: 34790170
doi: 10.3389/fendo.2021.749010
pmc: PMC8591164
doi:
Substances chimiques
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
749010Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK092485
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK114006
Pays : United States
Informations de copyright
Copyright © 2021 Shaffner, Chen, Malhotra, Dworkin and Gong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Pharmacol. 2007 Feb;71(2):628-34
pubmed: 17110502
PLoS One. 2013;8(2):e54442
pubmed: 23390498
Lancet Diabetes Endocrinol. 2021 Feb;9(2):106-116
pubmed: 33357505
Lancet Diabetes Endocrinol. 2020 Jul;8(7):582-593
pubmed: 32559474
Int J Mol Sci. 2019 Feb 01;20(3):
pubmed: 30717173
Metabolism. 2014 Oct;63(10):1228-37
pubmed: 25104103
Nat Commun. 2020 May 1;11(1):2127
pubmed: 32358544
J Am Soc Nephrol. 2018 Nov;29(11):2755-2769
pubmed: 30314978
Science. 2008 Aug 8;321(5890):810-4
pubmed: 18599740
Diabetes Obes Metab. 2020 Apr;22 Suppl 1:46-54
pubmed: 32267076
Lancet Diabetes Endocrinol. 2019 May;7(5):397-412
pubmed: 30579729
Diabetes. 2005 Dec;54(12):3427-34
pubmed: 16306358
Diabetes Care. 1990 Mar;13(3):198-208
pubmed: 2407475
Diabet Med. 2016 Dec;33(12):1732-1736
pubmed: 26927445
J Cell Biochem. 2018 Apr;119(4):2990-2998
pubmed: 29111576
J Clin Hypertens (Greenwich). 2018 Feb;20(2):411-412
pubmed: 29194943
Nephrol Dial Transplant. 2013 Sep;28(9):2221-8
pubmed: 23543594
Annu Rev Nutr. 2006;26:1-22
pubmed: 16848698
Diabetes Obes Metab. 2018 Feb;20(2):458-462
pubmed: 28846182
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
Horm Metab Res. 2015 Aug;47(9):686-92
pubmed: 25611208
Nat Med. 2015 May;21(5):512-7
pubmed: 25894829
Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854
pubmed: 31495651
Adv Ther. 2015 Dec;32(12):1177-91
pubmed: 26650815
Diabetes Obes Metab. 2015 Apr;17(4):426-9
pubmed: 25600248
PLoS One. 2014 Jun 24;9(6):e100777
pubmed: 24960177
J Clin Invest. 1995 Nov;96(5):2528-33
pubmed: 7593645
J Am Coll Cardiol. 2017 Aug 8;70(6):704-712
pubmed: 28619659
Saudi J Biol Sci. 2019 Feb;26(2):421-426
pubmed: 31485187
Kidney Int. 2018 Nov;94(5):912-925
pubmed: 30021702
BMJ Open Diabetes Res Care. 2020 May;8(1):
pubmed: 32448787
Diabetes Ther. 2020 Mar;11(3):711-723
pubmed: 32052281
Nephrol Dial Transplant. 2020 Jan 1;35(Suppl 1):i48-i55
pubmed: 32003833
Diabet Med. 2010 Feb;27(2):136-42
pubmed: 20546255
Cardiovasc Diabetol. 2019 Apr 5;18(1):46
pubmed: 30953516
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
Am J Physiol Endocrinol Metab. 2017 Nov 1;313(5):E563-E576
pubmed: 28811292
Kidney Int. 2021 Nov;100(5):1037-1053
pubmed: 34246657
Circulation. 2016 Sep 6;134(10):752-72
pubmed: 27470878
Physiol Rev. 2011 Apr;91(2):733-94
pubmed: 21527736
J Am Soc Nephrol. 2019 Nov;30(11):2229-2242
pubmed: 31530577
Sci Transl Med. 2018 Nov 14;10(467):
pubmed: 30429355
Oxid Med Cell Longev. 2012;2012:542042
pubmed: 23227274
Ther Adv Endocrinol Metab. 2016 Dec;7(5-6):212-228
pubmed: 28203358
Cell Metab. 2020 Jul 7;32(1):13-14
pubmed: 32640243
Ageing Res Rev. 2020 Nov;63:101151
pubmed: 32835891
Hum Genet. 2002 Jan;110(1):21-9
pubmed: 11810292
Cell Metab. 2017 Feb 7;25(2):262-284
pubmed: 28178565
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
Am J Physiol. 1999 Jan;276(1):E78-84
pubmed: 9886953
Diabetes Obes Metab. 2019 Apr;21(4):801-811
pubmed: 30407726
N Engl J Med. 2021 Jan 14;384(2):129-139
pubmed: 33200891
Physiol Rep. 2020 Jan;8(2):e14360
pubmed: 31994353
Front Med (Lausanne). 2018 May 31;5:160
pubmed: 29904633
Diabetes Care. 2001 Feb;24(2):382-91
pubmed: 11213896
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11753-8
pubmed: 13130073
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4111-9
pubmed: 26170283
J Am Soc Nephrol. 2020 May;31(5):1128-1139
pubmed: 32354987
J Am Soc Nephrol. 2011 Jan;22(1):104-12
pubmed: 20616166
Endocrine. 2015 Apr;48(3):730-42
pubmed: 25273317
Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F227-34
pubmed: 26041448